PHB7 Antibody

What is PAX7 and why is it an important research target?

PAX7 (Paired box protein Pax-7) is a transcription factor encoded by the PAX7 gene in humans. It is also known by several alternative designations including HUP1, PAX7B, and RMS2 . PAX7 plays critical roles in the specification and maintenance of muscle satellite cells, which are essential for skeletal muscle regeneration. This makes PAX7 antibodies invaluable tools for studying muscle development, regeneration processes, and various muscular disorders.

The methodological approach to studying PAX7 typically involves immunodetection in muscle tissue sections or cultured myogenic cells, where PAX7 serves as a definitive marker for satellite cell identification. Researchers commonly utilize PAX7 antibodies to investigate satellite cell populations in various physiological and pathological conditions, including aging, exercise-induced adaptation, and muscular dystrophies.

What are the key considerations for selecting the appropriate PAX7 antibody for my research?

Selecting the appropriate PAX7 antibody requires consideration of several experimental factors:

• Target species compatibility: Ensure the antibody recognizes PAX7 in your model organism. Many antibodies recognize human, mouse, and rat PAX7, but cross-reactivity with other species varies .

• Antibody type: Monoclonal antibodies (like PAX7/497 and PAX7/1187) offer high specificity for particular epitopes, while polyclonal antibodies may provide better sensitivity by recognizing multiple epitopes .

• Application compatibility: Verify the antibody has been validated for your specific application (WB, IHC-p, IF, FCM, ICC) .

• Epitope location: Consider which region of PAX7 the antibody targets (N-terminal, C-terminal, or middle region) as this may affect detection in different experimental contexts .

• Validation evidence: Review available validation data including images, citations, and specificity tests before selecting an antibody.

How should I design experiments to accurately quantify PAX7-positive satellite cells in muscle tissue?

For accurate quantification of PAX7-positive satellite cells, implement the following methodological approaches:

• Tissue preparation:

  • Use fresh frozen sections (8-10μm thick) for optimal epitope preservation

  • Fix briefly (10-15 minutes) with 4% paraformaldehyde to maintain antigenicity

  • For paraffin-embedded sections, optimize antigen retrieval methods (typically heat-mediated retrieval with citrate buffer)

• Staining protocol:

  • Include co-staining with laminin or dystrophin to outline muscle fibers

  • Add DAPI for nuclear counterstaining to confirm nuclear PAX7 localization

  • Consider co-staining with MyoD to distinguish between quiescent (PAX7+/MyoD-) and activated (PAX7+/MyoD+) satellite cells

• Quantification strategy:

  • Count PAX7+ nuclei relative to:

    • Total fiber number (PAX7+ cells/100 fibers)

    • Total area (PAX7+ cells/mm²)

    • Total myonuclei (percentage of PAX7+ nuclei)

  • Analyze multiple fields (minimum 5-10) from different muscle regions

  • Include biological replicates (n≥3) for statistical validity

• Controls:

  • Positive control: Include tissues known to express PAX7 (young mouse muscle)

  • Negative control: Secondary antibody only

  • Consider using PAX7 knockout/knockdown tissue when available

What are the optimal fixation and antigen retrieval methods for PAX7 immunostaining?

Optimization of fixation and antigen retrieval is critical for successful PAX7 immunostaining:

For frozen sections:

• Fix freshly cut sections with cold 4% paraformaldehyde for 10 minutes

• Alternative: 100% cold methanol for 10 minutes at -20°C works well for some PAX7 antibodies

• Permeabilize with 0.2-0.3% Triton X-100 in PBS for 10 minutes

• No antigen retrieval is typically needed for frozen sections

For paraffin-embedded tissues:

• Limit formalin fixation to 24-48 hours maximum

• Test both citrate buffer (pH 6.0) and EDTA buffer (pH 9.0) for antigen retrieval

• Perform heat-induced epitope retrieval (95-100°C for 20-30 minutes)

• Pressure cooker methods often yield superior results

Comparative results across fixation methods:

How can I implement PAX7 antibodies in flow cytometry for satellite cell isolation?

Implementing PAX7 antibodies in flow cytometry requires special consideration due to PAX7's nuclear localization:

• Cell preparation:

  • Enzymatically digest muscle tissue (collagenase/dispase method)

  • Filter cell suspension through 40-70μm strainers

  • Remove debris via Percoll gradient centrifugation if needed

• Fixation and permeabilization:

  • Fix cells with 2% paraformaldehyde (10 minutes)

  • Permeabilize with 0.2% Triton X-100 or commercial permeabilization buffer

  • For intranuclear staining, specialized nuclear permeabilization kits may yield better results

• Staining protocol:

  • Block with 2-5% serum matching secondary antibody host

  • Use primary PAX7 antibody at optimized concentration (typically 1:50-1:100)

  • Select fluorochrome-conjugated secondary antibodies with bright signals (e.g., Alexa Fluor 488 or 647)

  • Include viability dye to exclude dead cells

• Sorting strategy:

  • Combine PAX7 with surface markers (CD34, α7-integrin) for comprehensive satellite cell isolation

  • Set appropriate gates using FMO (Fluorescence Minus One) controls

  • Sort at low pressure (20-25 psi) to maintain cell viability

• Validation:

  • Confirm PAX7 expression in sorted populations by immunocytochemistry

  • Assess myogenic potential of sorted cells through differentiation assays

How can I troubleshoot weak or absent PAX7 antibody signal in Western blot applications?

When troubleshooting weak or absent PAX7 signal in Western blot applications, consider these methodological approaches:

• Protein extraction optimization:

  • Use specialized nuclear extraction buffers containing DNase

  • Include protease inhibitors to prevent degradation

  • Consider RIPA buffer with 0.1% SDS for more efficient extraction

• Loading considerations:

  • Increase protein loading (50-80μg for tissue samples)

  • Use nuclear-specific loading controls (Lamin B1, Histone H3)

  • Consider protein concentration methods for low-expression samples

• Transfer optimization:

  • Use PVDF membranes (0.45μm pore size) for better protein retention

  • Extend transfer time for high molecular weight proteins

  • Add 0.1% SDS to transfer buffer to improve elution from gel

• Detection enhancements:

  • Increase primary antibody concentration (1:250-1:500)

  • Extend primary antibody incubation (overnight at 4°C)

  • Use high-sensitivity ECL substrates or fluorescent detection systems

  • Consider signal amplification systems (biotin-streptavidin)

• Tissue-specific considerations:

  • Adult muscle has lower PAX7 expression than developing or regenerating muscle

  • Cultured satellite cells may downregulate PAX7 upon differentiation

  • Consider positive controls with known PAX7 expression

What are the strategies for performing double immunostaining with PAX7 and other satellite cell markers?

Effective double immunostaining with PAX7 requires careful protocol design:

• Antibody selection considerations:

  • Choose primary antibodies from different host species (e.g., mouse anti-PAX7 with rabbit anti-MyoD)

  • If using same-species antibodies, consider directly conjugated antibodies or sequential staining with blocking steps

  • Validate each antibody individually before attempting co-staining

• Optimized protocol for PAX7 double-staining:

  • Fix and permeabilize as appropriate for both targets

  • Block with serum from both secondary antibody host species

  • Apply both primary antibodies simultaneously if from different species

  • Use highly cross-adsorbed secondary antibodies to prevent cross-reactivity

  • Include separate nuclear counterstain (DAPI or Hoechst)

• Common PAX7 co-staining combinations and rationales:

• Controls for double-staining:

  • Single antibody controls to assess bleed-through

  • Secondary-only controls for each primary/secondary combination

  • Absorption controls with blocking peptides when available

How do I analyze contradictory results obtained with different PAX7 antibodies?

When faced with contradictory results from different PAX7 antibodies, implement this analytical framework:

• Antibody validation assessment:

  • Compare epitope locations of conflicting antibodies

  • Review validation data and citations for each antibody

  • Check for potential cross-reactivity with other PAX family members (especially PAX3)

• Systematic comparison approach:

  • Test both antibodies side-by-side on identical samples

  • Include positive and negative control tissues

  • Compare with mRNA expression data (qPCR or in situ hybridization)

  • When possible, include PAX7 knockout/knockdown samples as controls

• Technical considerations:

  • Different fixation methods may affect epitope availability

  • Antibody concentration may need optimization for each application

  • Some epitopes may be masked by protein-protein interactions or post-translational modifications

• Resolution strategies:

  • Use a third PAX7 antibody targeting a different epitope as a tiebreaker

  • Employ genetic approaches (PAX7 reporter models) to confirm findings

  • Consider mass spectrometry to verify protein identity

  • Combine antibody detection with functional assays to validate biological relevance

What statistical approaches are appropriate for analyzing PAX7-positive cell quantification data?

Appropriate statistical analysis of PAX7+ cell quantification should follow these methodological principles:

• Experimental design considerations:

  • Determine appropriate sample size through power analysis

  • Account for biological variation between animals/patients

  • Use randomization and blinding where possible

• Data distribution assessment:

  • Test for normality using Shapiro-Wilk or Kolmogorov-Smirnov tests

  • Examine data histograms for distribution patterns

  • Consider transformations for non-normally distributed data

• Statistical test selection:

  • For normally distributed data:

    • Two groups: Student's t-test (paired or unpaired)

    • Multiple groups: One-way ANOVA with appropriate post-hoc tests

    • Multiple variables: Two-way ANOVA for factorial designs

  • For non-parametric data:

    • Two groups: Mann-Whitney U test or Wilcoxon signed-rank test

    • Multiple groups: Kruskal-Wallis with Dunn's post-hoc test

• Advanced analytical approaches:

  • Mixed-effects models for repeated measures designs

  • ANCOVA when controlling for covariates (e.g., age, sex)

  • Correlation analysis for relationships between PAX7+ cells and functional outcomes

• Reporting standards:

  • Include both means/medians and measures of dispersion (SD, SEM, IQR)

  • Report exact p-values rather than thresholds

  • Include confidence intervals when possible

  • Clearly state biological vs. technical replication numbers

How can I address non-specific binding and high background when using PAX7 antibodies?

Non-specific binding and high background are common challenges with PAX7 immunostaining. Implement these methodological solutions:

• Blocking optimization:

  • Extend blocking time (1-2 hours at room temperature)

  • Test different blocking agents (BSA, serum, commercial blockers)

  • For mouse monoclonal antibodies on mouse tissue, use specialized Mouse-on-Mouse blocking kits

  • Add 0.1-0.3% Triton X-100 to blocking buffer for better penetration

• Antibody optimization:

  • Titrate antibody concentration to determine optimal dilution

  • Consider longer incubation (overnight at 4°C) with more dilute antibody

  • Pre-absorb antibody with non-specific proteins (liver powder, BSA)

  • Use purified IgG rather than serum or ascites preparations

• Washing enhancement:

  • Increase number of washes (5-6 times for 5-10 minutes each)

  • Add 0.05-0.1% Tween-20 to wash buffers

  • Include 0.1-0.5% BSA in wash buffers to reduce non-specific binding

  • Use gentle agitation during washing steps

• Tissue-specific considerations:

  • For autofluorescent tissues, include Sudan Black B treatment

  • Block endogenous peroxidase activity for HRP-detection systems

  • For fibrotic tissues, increase detergent concentration in all buffers

  • Consider antigen retrieval optimization for fixed tissues

How do I distinguish true PAX7 expression from artifacts in immunohistochemistry?

Distinguishing true PAX7 expression from artifacts requires rigorous controls and careful interpretation:

• Characteristic features of true PAX7 staining:

  • Exclusively nuclear localization

  • Satellite cell position (beneath basal lamina)

  • Appropriate intensity relative to background

  • Consistency with known biological distribution

• Critical controls to validate staining:

  • Negative controls: secondary antibody only, isotype control

  • Positive controls: tissues with known PAX7 expression

  • Absorption controls: pre-incubation with blocking peptide

  • Genetic controls: PAX7 knockout/knockdown tissues when available

• Common artifacts and resolution strategies:

• Advanced validation methods:

  • In situ hybridization for PAX7 mRNA to confirm protein expression

  • Multiple antibodies targeting different PAX7 epitopes

  • Correlation with functional characteristics of PAX7+ cells

How can PAX7 antibodies be utilized in single-cell analysis technologies?

PAX7 antibody applications in single-cell technologies require specialized methodological approaches:

• Single-cell proteomics integration:

  • CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing):

    • Requires conjugation of PAX7 antibodies to oligonucleotide barcodes

    • Enables simultaneous detection of PAX7 protein and whole transcriptome

    • Requires specialized nuclear permeabilization protocols

  • Mass cytometry (CyTOF):

    • Requires metal-conjugated PAX7 antibodies

    • Allows high-dimensional analysis with 30+ markers

    • No fluorescence spillover concerns

• Imaging-based single-cell analysis:

  • Imaging mass cytometry:

    • Metal-labeled PAX7 antibodies for tissue imaging

    • Spatial context preservation with 1μm resolution

    • Multiplex with 30+ markers simultaneously

  • CODEX (CO-Detection by indEXing):

    • DNA-barcoded PAX7 antibodies

    • Iterative imaging for highly multiplexed detection

    • Preserves tissue architecture

• Methodological optimization for single-cell techniques:

  • Enhanced fixation and permeabilization for nuclear transcription factors

  • Antibody validation in single-cell contexts

  • Computational methods for integrating protein and transcript data

  • Spatial analysis workflows for tissue-based approaches

What are the challenges in using PAX7 antibodies for studying satellite cell dynamics in aged or diseased muscle?

Studying satellite cells in aged or diseased muscle presents specific challenges for PAX7 antibody applications:

• Technical challenges in aged/diseased tissues:

  • Increased autofluorescence requiring specialized quenching techniques

  • Fibrosis limiting antibody penetration

  • Altered antigen retrieval requirements due to ECM changes

  • Potential epitope masking from protein aggregation

• Biological interpretation complexities:

  • Reduced satellite cell numbers requiring analysis of more fields/sections

  • Altered PAX7 expression levels affecting detection sensitivity requirements

  • Heterogeneous satellite cell populations requiring multiple marker panels

  • Changed satellite cell positioning relative to basal lamina

• Methodological adaptations:

  • Enhanced antigen retrieval for fibrotic tissues (extended protease digestion)

  • Lipofuscin autofluorescence reduction protocols (Sudan Black B)

  • Signal amplification methods for low abundance detection

  • 3D imaging approaches to capture rare cells throughout tissue volume

• Validation requirements:

  • Age-matched controls for comparative analysis

  • Multiple biological replicates to account for increased variability

  • Correlation with functional satellite cell assays (activation potential)

  • Combined protein and mRNA detection approaches